Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lifeline for HAE patients: study offers continued access to promising drug

NCT ID NCT04933721

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 24 times

Summary

This study provides ongoing access to berotralstat for up to 139 people with hereditary angioedema (HAE) who previously took part in berotralstat trials. The main goal is to monitor safety and side effects over time. Participants take the medication daily to help control their condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Study Center

    Ottawa, Canada

  • Study Center

    Brno, Czechia

  • Study Center

    Pilsen, Czechia

  • Study Center

    Grenoble, France

  • Study Center

    Marseille, France

  • Study Center

    Paris, France

  • Study Center

    Frankfurt, Germany

  • Study Center

    Skopje, North Macedonia

  • Study Center

    Krakow, Poland

  • Study Center

    Martin, Slovakia

  • Study Center

    Cape Town, South Africa

  • Study Center

    Daegu, South Korea

  • Study Center

    Gwangju, South Korea

  • Study Center

    Seoul, South Korea

  • Study Center

    Madrid, Spain

  • Study Center

    Bristol, United Kingdom

Conditions

Explore the condition pages connected to this study.